Fig. 6

Nilotinib suppresses LPS-stimulated P38/STAT3 signaling in primary astrocytes. a, c, e Western blotting analysis of p-P38/p-AKT signaling and p-STAT3/NF-kB transcription factors in LPS-treated primary astrocytes post-treated with nilotinib as shown (n = 5/group). b, d, f, g Immunocytochemistry analysis of p-P38, p-AKT, p-STAT3, and p-NF-kB levels in LPS-treated primary astrocytes post-treated with nilotinib as shown (p-P38, C: n = 17; L: n = 26; L + Nil: n = 15, p-AKT, C: n = 25; L: n = 30; L + Nil: n = 18, p-STAT3, C: n = 126; L: n = 128; L + Nil: n = 173, p-NF-kB, C: n = 203; L: n = 229; L + Nil: n = 213). C: control, L: LPS, L + Nil: LPS + nilotinib, *p < 0.05, **p < 0.01, ***p < 0.001, scale bar = 20 μm